Oculis Holding AG announced that the final patient visit has been completed in the DIAMOND phase 3 program assessing OCS-01, ...
4D Molecular Therapeutics reports positive interim data for 4D-150 in wet AMD and DME, with strong financial position and strategic focus. 4D Molecular Therapeutics announced positive interim data for ...
EyePoint's Duravyu, a potential "best-in-class" therapy for Wet AMD and DME, could disrupt the market with fewer injections required compared to Eylea and Vabysmo. Positive Phase 2 DME data and ...
Across all DME patients dosed to date, 4D-150 continues to be well tolerated with no intraocular inflammation observed at any timepoint or dose level 3E10 vg/eye demonstrated strong signals of ...
Image source: The Motley Fool. EyePoint Pharmaceuticals (NASDAQ:EYPT) advanced its lead candidate, DuraVu, through rapid phase 3 enrollment in wet AMD and aligned phase 3 DME trial initiation while ...
Please provide your email address to receive an email when new articles are posted on . EyePoint Pharmaceuticals has announced positive 16-week data from the ongoing phase 2 VERONA trial evaluating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results